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Evaluation of Quality of Life in Dogs with Idiopathic Epilepsy
A. Wessmann, H.A. Volk, T. Parkin, M. Ortega, and T.J. Anderson
Background: The impact of epilepsy and its treatment on the quality of life (QoL) is considered an important part of
treatment supervision in human epilepsy.
Objectives: To develop a list of key questions evaluating QoL in dogs with idiopathic epilepsy (IE) and their carers.
Animals: One hundred fifty-nine dogs with IE.
Methods: Cross-sectional study. An online project questionnaire was developed containing 90 QoL-associated questions
that were initially allocated to 14 themes representing specific areas associated with the treatment and care of an epileptic
dog. Principal component analysis was applied with the aim of refining the questionnaire to the least number of questions
representing useful themes without loss of descriptive value. Carers were recruited by paper mail, primary practices, and
canine epilepsy websites. Data were acquired from January to November 2011.
Results: Principal component analysis removed 54 questions, leaving 7 themes with 36 questions with a minimum
Cronbach’s alpha value of 0.7 indicating a good internal consistency: “Seizure severity and frequency”, “Adverse effects of
antiepileptic drug (AED)”, “Restrictions on the carer’s life”, “Frustrations over caring for a dog with IE”, “Carer distaste
of AED adverse effects”, “Carer anxiety around the seizure event”, “Perceptions on rectal diazepam use”.
Conclusions and Clinical Importance: Principal component analysis successfully reduced the number of questions with-
out loss in descriptive value. The remaining questions correlate well with each other in capturing valuable details about
aspects of QoL and represent valuable key questions (EpiQoL) in the assessment of QoL for the carers of dogs with IE.
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The World Health Organization (WHO) has definedhealth-related quality of life (QoL) as encompass-
ing physical, social, and neurobehavioral domains of
health as perceived by the patient1 and the QoL aspect
is considered an important aspect of the success of
treatment and supervision in humans.2,3 The physical
and behavioral impacts of idiopathic epilepsy (IE) and
its treatment on dogs are well established,4,5 yet its
impact on the perceived QoL is unclear. Studies of epi-
lepsy in dogs have indicated that the QoL of their pet
was an important aspect of treatment success for ca-
rers and moreover, that epilepsy in dogs affects the
carer’s and the dog’s QoL.4 Similar to studies of
human epilepsy, a recent study of IE in dogs included
a QoL questionnaire in the assessment of treatment
success of an antiepileptic drug (AED) and identified
AED-dependent QoL scores.5
The aim of this prospective study was to develop a
disease-specific QoL list of key questions (EpiQoL) for
the carers of dogs with IE based on the multidimen-
sional aspects of QoL as defined by the WHO into
physical, social, and neurobehavioral domain adapted
for IE in dogs. A project questionnaire was designed
to enquire into a broad range of aspects affected by IE
with a variety of questions, and the study analyzed the
response with the aim of reducing the question number
through principal component analysis (PCA) to
achieve a reliable and easy-to-use list of key questions
to recommend for future use.
Material and Methods
Project Questionnaire Design
A trial questionnaire was designed with questions that were
considered relevant for carers of dogs with IE. Questions were
created based on the experience of veterinary specialists, pub-
lished questionnaires for dogs4 and from adults and adoles-
cents with epilepsy (http://www.epilepsy.com/pdfs/qolie_ad_48.
pdf; http://professionals.epilepsy.com/pdfs/qolie_31.pdf). The trial
questionnaire was evaluated by 2 panels, initially by 9 informed
veterinary surgeons, and subsequently by 8 informed carers of
epileptic dogs. Feedback about the appropriateness of the ques-
tions was used to modify the project questionnaire.
Project Questionnaire Description
The first section consisted of 90 close-ended QoL-associated
questions that targeted specific QoL areas potentially affected by
IE in dogs. All questions used an interval rating (Likert-type
scale, 1–5 [n = 88], 1–7 [n = 2]). The second section included 29
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close-ended questions concerning factual data such as diagnosis,
seizure onset, seizure description, and seizure management
including AED and adverse effects. The third section included 14
close-ended questions enquiring about general factual details of
the dog and the carer.
The 90 QoL-associated questions in the first section were allo-
cated to 14 themes. Four questions represented more than 1
theme and these questions (Table S1) were repeated in a second
theme for the statistical evaluation. A total of 90 questions plus
4 repeated questions were allocated to the following themes: (1)
“Seizure severity and frequency” (5 questions), (2) “Adverse
effects of AED” (12 questions), (3) “Positive items” observations
indicating a positive influence on the carer of being responsible
for a dog with IE (3 questions), (4) “Behavioral changes in the
dog associated with the onset of the epilepsy” (7 questions), (5)
“Organizational aspects of seizure management” (6 questions),
(6) “Restrictions on the carer’s life” (10 questions), (7) “Impor-
tance of support from other people” (3 questions), (8) “Frustra-
tions over caring for a dog with IE” (11 questions), (9) “Carer
distaste of AED adverse effects” (13 questions), (10) “Carer anx-
iety around the seizure event” (7 questions), (11) “Carer
concerns around seizure management” (4 questions), (12) “Per-
ceptions on rectal diazepam use” (4 questions), (13) “Financial
implications of caring for a dog with IE” (3 questions), and (14)
“Impact on carer’s QoL through caring for a dog with IE” (6
questions).
Physical, Social, and Neurobehavioral Domains
The themes of the project questionnaire were further allocated
to physical, social, and neurobehavioral domains of the dog and
the carer, adapted from human epilepsy research.2 Themes 1 and
2 were considered to affect the physical domain of the epileptic
dog, themes 3 and 4 the social domain, and theme 4 the neurobe-
havioral domain as assessed by the carer. The physical domain of
a carer was considered not to be affected by IE in dogs. Themes
3–8 were considered to affect the social domain, and themes 1
and 7–14 were considered to affect the neurobehavioral domain
of a carer responsible for an epileptic dog.
Recruitment of Responders
The project questionnaire was presented online via the online
survey software and questionnaire tool SurveyMonkey (http://
www.surveymonkey.com). The opportunity to take part in the
survey was announced through email contact via 800 primary
practices and by canine epilepsy websites. Carers of dogs diag-
nosed with IE at the authors’ institutions (UGVS, RVC) were
invited by paper mail publicizing a link to the online project
questionnaire. A UK canine epilepsy website (http://www.cani-
neepilepsy.co.uk) publicized the online study. Data were acquired
from January to November 2011. The principal investigators had
access to all data with client details removed for further statistical
analysis. Ethics approval was granted by the University of Glas-
gow Faculty of Veterinary Medicine ethics committee and by the
Royal Veterinary College ethics committee (ethical approval
number URN 2010 1077).
Response Inclusion Criteria
Responses were included if they referred to dogs with recur-
rent seizures (>2) which were either presumptively diagnosed with
IE following substantial investigation, including normal brain
imaging (MRI or CT) and cerebrospinal fluid analysis indepen-
dent of the age of onset or strongly suspected to have IE with
seizures for more than 1 year and an age of onset between
6 months and 6 years. Responses were excluded if the dogs
referred to were not alive at the time of completion of the project
questionnaire or if other diseases that required ongoing veteri-
nary treatment or attention were identified (eg, arthritis), to limit
other factors potentially affecting assessment of the dog’s QOL.
Statistical Analysis
Principal component analysis was used to examine the interre-
lations among the questions within each theme and to maximize
the internal consistency (reliability) within each theme by reduc-
ing the number of questions to a minimum representing the same
theme.3 PCA plots were examined to identify questions that were
most likely to be related. Item analysis was conducted to calcu-
late Cronbach’s alpha values to identify the degree of agreement
between questions within a theme.3,6 A cutoff value of 0.7 or
higher was used in this study, as this is generally believed to be
an acceptable reliability coefficient for questionnaire-based stud-
ies.6 PCA was performed on each theme and questions were
removed until the highest possible Cronbach’s alpha value or at
least a value of 0.7 was achieved and these questions were
included in the EpiQoL. Statistical analysis was performed by the
statistical software package Minitab 16.a
Results
Descriptive Data
Three hundred eighty-one carers participated in the
study. The responses described 159 affected dogs meet-
ing the inclusion criteria distributed over 50 breeds but
including 30 crossbreed dogs; mean age of 5.8 years
(median 5.2 years, range 0.7–12.5 years), 66 female (52
neutered) and 93 male dogs (67 neutered). Two hun-
dred twenty-two dogs were excluded because of not
fulfilling the criteria of suspected to have IE (121),
diagnosis other than IE (18), death (17), and treatment
for other diseases (66) such as arthritis, pancreatitis, or
liver dysfunction.
The mean age of onset was 2.7 years (median
2 years, range 0.3–9 years). Seizure frequency was sta-
ted as “more often than every week” in 5%, “every
week” in 5%, “every 2 weeks” 15%, “every month” in
29%, “every 2 months” in 11%, “every 3-6 months”
in 16%, and “less than 1 seizure every 6 months” in
19% of dogs.
Statistical Analysis
The 14 themes of the first section of the project
questionnaire underwent PCA. A model was created
with 7 themes (1, 2, 6, 8, 9, 10, 12) comprising 36
questions included in the EpiQoL which achieved a
minimum Cronbach’s alpha value of 0.7 ranging from
0.77 to 0.93 (median 0.79) (Table 1). For 7 themes,
the Cronbach’s alpha values were <0.7 (3, 4, 5, 7, 11,
13, 14) and those themes were excluded from the
EpiQoL.
Physical, Social, and Neurobehavioral Domains
The themes remaining following PCA were themes
1 and 2 characterizing the physical domain of an
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epileptic dog, themes 6 and 8 characterizing the social
domain of a carer, and themes 8–10, and 12 character-
izing the neurobehavioral domain of the carer respon-
sible for an epileptic dog.
Discussion
This study has developed a disease-specific carer-
based list of key questions for collecting data on a
Table 1. Final QoL-associated questionnaire showing 7 themes with Cronbach’s alpha values above 0.7 indicating
a good internal consistency and reliability.
QoL-Associated Questionnaire Themes and Questions
Cronbach’s Alpha per Theme
(scale dimension per question)
1. Seizure severity and frequency CA: 0.85
1. In the last 3 months, the frequency of the fits in my dog was acceptable 1–5 (strongly agree–strongly disagree)
2. In the last 3 months, the severity of the fits in my dog was acceptable
3. In the last 3 months, overall, the fits in my dog are managed successfully
4. Overall, how severe were your dog’s fits in the past 3 months? 1–7 (very mild–very severe)
2. Adverse effects of AED CA: 0.77
1. In the past 3 months, the adverse effects of the medication to control the
fits in my dog were acceptable
1–5 (strongly agree–strongly disagree)
In the past 3 months, how severe was the following adverse effect:
2. Eating more/would like to eat more 1–5a (very mild–very severe)
3. Gaining weight
4. Drinking more
5. Urinating more
6. Sleeping more than before
7. Wobbly/not coordinated when walking
8. Restlessness/pacing
9. Itchiness or skin rash
10. Vomiting
11. Diarrhea
12. Coughing
6. Restrictions on the carer’s life (related to caring for a dog with IE) CA: 0.71
1. In the past 3 months, how often did you feel that your dog’s epilepsy
caused conflict with your work, education, or day-to-day activities?
1–5 (never–very often)
2. In the past 3 months, how often did you feel that your dog’s epilepsy
limited your social life?
3. In the past 3 months, how often did you feel that your dog’s epilepsy
limited your independence?
8. Frustrations over caring for a dog with IE CA: 0.93
1. My limitations in work, education or day-to-day activities because of
my dog’s fits
1–5 (not at all bothersome–extremely
bothersome)
2. My social limitations because of my dog’s fits
3. Overall, the limitations on my life caring for my epileptic dog
9. Owner distaste of AED adverse effects CA: 0.79
1. How bothersome are the physical effects of the medication on my dog? 1–5b (not at all bothersome–extremely
bothersome)2. How bothersome are the mental effects of the medication on my dog?
In the past 3 months, how much did you dislike the following adverse effects:
3. Eating more/would like to eat more 1–5a (not at all–a lot)
4. Gaining weight
5. Drinking more
6. Urinating more
7. Sleeping more than before
8. Wobbly/not coordinated when walking
9. Restlessness/pacing
10. Coughing
10. Carer anxiety around the seizure event (and its effects on the dog) CA: 0.89
1. In the last 3 months, I worried about the frequency of the fits in my dog 1–5 (strongly disagree–strongly agree)
2. In the last 3 months, I worried about the severity of the fits in my dog
12. Perceptions of rectal diazepam use CA: 0.78
1. Have you ever been uncertain when to give rectal diazepam? 1–5b (never–always)
2. Have you ever been worried how much or how often you are supposed
to give rectal diazepam
CA, Cronbach’s alpha; IE, idiopathic epilepsy.
aAdditional tick box: adverse effect not present.
bAdditional tick box: not applicable.
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wide spectrum of different aspects of IE in dogs con-
centrating on the QoL assessment on the individual
carer’s perception, as is emphasized in people.3,7 In
childhood epilepsy, the patients cannot undertake the
assessment for themselves. Therefore, the carer (mostly
the parent) performs successfully the assessment of the
QoL of an epileptic child. Similarly, the assessment is
performed by the carer in an epileptic dog and this is
believed to deliver meaningful results.8
Statistical modeling using PCA successfully reduced
the number of questions without loss in descriptive
value. A cutoff value of 0.7 or higher is generally
believed to represent an acceptable reliability coeffi-
cient6 and as a criterion for question retention success-
fully excluded 7 themes from the EpiQoL. The
remaining 7 themes were included in the EpiQoL and
are “Seizure severity and frequency”, “Adverse effects
of AED”, “Restrictions on the carer’s life”, “Frustra-
tions over caring for a dog with IE”, “Carer distaste
of AED adverse effects”, “Carer anxiety around the
seizure event”, and “Perceptions on rectal diazepam
use.” The mean Cronbach’s alpha value of 0.82 exhib-
ited good internal consistency indicating good face
validity, suggesting appropriate grouping of questions
and indicating that these themes can be reliably and
easily assessed with the EpiQoL.
The themes were allocated to physical, social, and
neurobehavioral domains focusing on the dog’s
and carer’s QoL. This approach was adapted from
research on humans1,2 and it is recommended that
measures of QoL should consider the impact of a
condition and its treatment on these domains (physi-
cal, social, and neurobehavioral).2 Disease-specific
measures are the most appropriate measures for
assessing treatment effects in clinical trials because
elements within each domain might vary between dif-
ferent disorders and occasionally elements relate to
more than one domain.3 For example, outcome of
measures such as seizure severity and frequency can
not only have a physical effect but the occurrence
itself or the expectations of treatment also have an
impact on the perceived QoL.3 Only the physical
domain affecting the epileptic dog reached good inter-
nal consistency, whereas 5 themes of the social and
neurobehavioral domains affecting the carer caring
for an epileptic dog remained in the EpiQoL. Like-
wise, it is well known that childhood epilepsy not
only affects the QoL of the affected child but also of
the carer.9 The factors correlated with carer QoL in
childhood epilepsy are seizure control; the incidence
of status epilepticus; AED adverse effects; the mani-
festation of anxiety and depression in an affected
child.9 The effect of IE in dogs on the carer’s QoL is
also reported in veterinary medicine4 but the impor-
tance is unknown. It is likely that the impact of car-
ing for a dog with IE on the carer’s QoL influences
decisions they make regarding treatment or euthana-
sia and thus requires consideration when treatment
options are discussed.
Quality of life in epileptic persons is assessed with
subjective and objective outcome measures.7 Engel
proposed a postoperative classification system for epi-
leptic human patients and introduced a seizure fre-
quency score using objective and subjective
terminology.7 Subjective vocabulary such as “worth-
while improvement” made comparison of studies chal-
lenging. Thus, Wieser suggested that seizure outcome
classification and QoL classification should be sepa-
rately assessed.7 Moreover, as epilepsy might change
during time and QoL can be variably annual QoL
assessment is recommended. This study addresses the
subjective assessment of QoL in epilepsy in dogs.
Therefore, the EpiQoL could be used for subjective
assessment of QoL in future studies of epilepsy in dogs
and be part of comprehensive QoL assessment if com-
bined with objective outcome measures. When the goal
is to measure QoL, it should be used on a year-by-year
basis as epilepsy might change during time, and QoL
can be variably.
A limitation of this study is that the influence indi-
vidual factors have on the QoL in dogs are not well
understood and therefore were extrapolated from
research in human epilepsy and the experience of expe-
rienced clinicians dealing with epilepsy in dogs. It is
possible that how carers feel about their dog’s epilepsy,
the perception of their own QoL, and also the carers’
social education and geographical differences (eg,
rural/urban, different countries) are correlated with the
assessment of the dog’s QoL. Additionally, PCA iden-
tified critical and noncritical questions to identify the
minimum number of questions necessary to evaluate
the internal consistency of a theme and did not assess
the loading, a factor might have on the QoL. Ideally,
a validation of the key questions is performed in com-
parison with a gold standard. However, a gold stan-
dard assessment of QoL in IE in dogs is not available.
Thus, we relied on construct validity, which is based
on predictions about how the result of the question-
naire should correlate with other related or nonrelated
measures. The results confirmed the relations, which
therefore support construct validity. Construct validity
is the main requirement of any measuring tool and can
neither be proved nor disproved on the basis of a sin-
gle study.8
Studies investigating the QoL in IE in dogs used
QoL questionnaires, uniquely developed for each
study,5 making it difficult to compare the QoL assess-
ment between studies. The final questionnaire of this
study provides future studies with a limited number of
key questions assessing QoL in IE in dogs without loss
in value evaluating a wide variety of topics associated
with IE in dogs. The final aim was to develop a gold
standard assessing the QoL in IE in dogs and the here
presented questionnaire provides a set of key questions
investigating the QoL in IE in dogs for future studies.
Further studies are necessary to assess the loading of
the items and based on this to finally develop a scor-
ing system that enables evaluating outcome and com-
paring QoL between patients and between studies.
Thus, future studies using the EpiQoL are needed to
assess the usefulness in QoL assessment in epilepsy in
dogs.
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Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Table S1. Questionnaire items investigating the
perception of the participant on aspects affected by
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